Back to top
more

Ascendis Pharma (ASND)

(Delayed Data from NSDQ)

$124.28 USD

124.28
974,853

-1.75 (-1.39%)

Updated Nov 14, 2024 04:00 PM ET

After-Market: $119.00 -5.28 (-4.25%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (71 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

New Strong Sell Stocks for January 13th

by Zacks Equity Research

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.

Implied Volatility Surging for Ascendis Pharma (ASND) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Ascendis Pharma (ASND) stock based on the movements in the options market lately.

Why Earnings Season Could Be Great for Ascendis (ASND)

by Zacks Equity Research

Ascendis (ASND) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Sorrento (SRNE) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Sorrento (SRNE) will provide updates on earnings and revenues when its releases third-quarter 2020 results.

Catalyst (CPRX) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Catalyst (CPRX) will provide updates on earnings and revenues when its releases third-quarter 2020 results.

Ascendis Progresses With Hypoparathyroidism Drug TransCon PTH

by Zacks Equity Research

Ascendis Pharma (ASND) reports encouraging preliminary data on its hypoparathyroidism candidate, TransCon PTH. A late-stage study is anticipated to begin soon.

BioMarin (BMRN) Files NDA for Vosoritide to Treat Dwarfism

by Zacks Equity Research

BioMarin's (BMRN) BLA for vosoritide is based on final data from a phase III study, long-term data from the ongoing phase II and phase III extension studies and extensive natural history data.

BioMarin's MAA for Dwarfism Candidate Gets EMA Validation

by Zacks Equity Research

The EMA sanctions BioMarin's (BMRN) marketing authorization application for vosoritide to treat children with achondroplasia, the most common type of dwarfism.

Ascendis' Dwarfism Candidate Gets Orphan Drug Status in EU

by Zacks Equity Research

Ascendis' (ASND) TransCon CNP receives an Orphan Drug tag in Europe for the treatment of achondroplasia, the most common type of dwarfism.

Ascendis Submits BLA to FDA for TransConhGH in Pediatric GHD

by Zacks Equity Research

Ascendis Pharma (ASND) submits BLA to the FDA for TransConhGH for the treatment of pediatric growth hormone deficiency.

Biomarin to File Regulatory Applications for Vosoritide in Q3

by Zacks Equity Research

BioMarin (BMRN) plans to file regulatory applications seeking approval for its achondroplasia candidate, vosoritide, in the third quarter of 2020.

BlackBerry (BB) to Report Q4 Earnings: What's in the Offing?

by Zacks Equity Research

BlackBerry's (BB) fiscal fourth-quarter performance is likely to have benefited from its investment in product development and go-to-market strategy.

What's in Store for Science Applications' (SAIC) Q4 Earnings?

by Zacks Equity Research

Science Applications' (SAIC) fourth-quarter fiscal 2020 results are likely to reflect gains from new business wins and the Engility acquisition.

Ascendis Pharma (ASND): Strong Industry, Solid Earnings Estimate Revisions

by Zacks Equity Research

Ascendis Pharma (ASND) has seen solid estimate revision activity over the past month, and belongs to a strong industry as well.

Ascendis Pharma A/S (ASND) Moves to Buy: Rationale Behind the Upgrade

by Zacks Equity Research

Ascendis Pharma A/S (ASND) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Alkermes (ALKS) to Report Q4 Earnings: What's in Store?

by Zacks Equity Research

We expect Alkermes (ALKS) to provide revenue updates on its proprietary marketed products and pipeline candidates when it releases fourth-quarter earnings on Feb 13.

Zoetis (ZTS) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Zoetis Inc. (ZTS) will provide financial numbers for fourth-quarter 2019 and pipeline updates on Feb 13.

Emmaus (EMMA) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Investors look forward to updates on key drug Endari's expansion plans when Emmaus (EMMA) releases fourth-quarter 2019 results.

Top Ranked Momentum Stocks to Buy for November 21st

by Zacks Equity Research

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, November 21st

Top Ranked Momentum Stocks to Buy for November 18th

by Zacks Equity Research

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, November 18th

What's in Store for Helmerich & Payne (HP) in Q4 Earnings?

by Zacks Equity Research

Helmerich & Payne's (HP) much popular technologically-advanced FlexRigs with strong daily rate margins might reflect on segmental profits in the to-be-reported results.

Kinjel Shah headshot

5 Biotech Stocks Set to Beat Q3 Earnings Estimates

by Kinjel Shah

Here we highlight five biotech companies, which are expected to deliver positive earnings surprises in this earnings season.

CannTrust (CTST) to Report Q3 Earnings: What's in Store?

by Zacks Equity Research

On CannTrust's (CTST) third-quarter earnings call, investor focus will be on the company's efforts to regain licenses for producing and selling cannabis.

Zoetis (ZTS) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Zoetis (ZTS) is expected to provide pipeline updates during the third-quarter earnings call.

Ascendis Pharma A/S (ASND) Upgraded to Buy: Here's Why

by Zacks Equity Research

Ascendis Pharma A/S (ASND) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.